Buying after a heavy sell off due to disappointing trial results
Oversold (as per the chat the stock reacts strongly to being oversold)
PPMO data expected in 2Q21 could prove a huge catalyst for shares to go higher
Also - the company is posting strong sales growth (+40% this year) and peak sales estimates are over double current sales of some treatments suggesting sales growth will continue.
Oversold (as per the chat the stock reacts strongly to being oversold)
PPMO data expected in 2Q21 could prove a huge catalyst for shares to go higher
Also - the company is posting strong sales growth (+40% this year) and peak sales estimates are over double current sales of some treatments suggesting sales growth will continue.